Dysautonomia: Insights on prognosis and related aspects
Dysautonomia, a condition that affects the autonomic nervous system (ANS), is a complex and often misunderstood health issue. The ANS is responsible for controlling involuntary functions such as heart rate, blood pressure, and digestion.
Common types of dysautonomia include Postural Orthostatic Tachycardia Syndrome (POTS), neurocardiogenic (autonomic mediated) syncope, multiple system atrophy (MSA), pure autonomic failure (PAF), and conditions related to neurodegenerative diseases such as Parkinson’s disease and Lewy body dementia.
POTS, characterized by an excessive increase in heart rate upon standing and symptoms like blood pooling and orthostatic intolerance, often occurs with conditions like Ehlers-Danlos Syndrome (EDS) and usually does not significantly reduce life expectancy, though it can greatly affect quality of life.
Neurocardiogenic syncope involves fainting due to autonomic nervous system malfunction but tends to be less severe in terms of life expectancy impact.
Multiple system atrophy (MSA) and pure autonomic failure (PAF) are more severe and typically affect older adults. MSA is a progressive neurodegenerative disorder with symptoms like muscle stiffness, bladder problems, and autonomic failure, and it generally has a poorer prognosis that can reduce life expectancy. PAF is characterized by loss of autonomic reflexes causing orthostatic hypotension and other dysfunctions but generally progresses slower than MSA; its impact on life expectancy varies but is often less dire than MSA.
Parkinson’s disease and Lewy body dementia commonly involve autonomic dysfunction and, as progressive neurodegenerative diseases, can reduce life expectancy depending on severity and complications.
In summary, life expectancy varies by dysautonomia type:
| Dysautonomia Type | Effect on Life Expectancy | |----------------------------|----------------------------------------------------| | POTS | Generally normal life expectancy | | Neurocardiogenic syncope | Usually normal life expectancy | | Pure autonomic failure (PAF) | Variable; often normal to moderately reduced | | Multiple system atrophy (MSA) | Typically reduced due to progressive neurodegeneration | | Parkinson’s disease / Lewy body dementia | Reduced depending on disease progression |
Most non-neurodegenerative dysautonomias like POTS do not significantly affect life expectancy but can be disabling and require management. In contrast, neurodegenerative-related autonomic failures tend to reduce life expectancy due to progressive nervous system decline.
FD, a debilitating condition present from birth, affects nerve cells in the ANS and is associated with a high mortality rate and a high incidence of sudden death. It is characterized by difficulty swallowing, poor control of blood pressure, body temperature, and breathing, inability to make tears, inability to feel pain, vomiting episodes, frequent episodes of pneumonia, and difficulty walking.
Chronic dysautonomia, such as FD, is ongoing and worsens over time. According to some studies, the annual mortality rate for fainting can range from 0-12% in people with no cardiac cause and 18-33% in people with a cardiac cause.
Understanding the various types of dysautonomia and their impact on life expectancy is crucial for effective management and treatment. If you or someone you know is experiencing symptoms associated with dysautonomia, it is essential to seek medical advice.
[1] Dysautonomia International. (n.d.). Dysautonomia Types. Retrieved from https://dysautonomiainternational.org/dysautonomia-types/
[2] Mayo Clinic. (2021). Postural orthostatic tachycardia syndrome (POTS). Retrieved from https://www.mayoclinic.org/diseases-conditions/postural-orthostatic-tachycardia-syndrome/symptoms-causes/syc-20358748
[5] National Institute of Neurological Disorders and Stroke. (2021). Multiple System Atrophy (MSA). Retrieved from https://www.ninds.nih.gov/Disorders/All-Disorders/Multiple-System-Atrophy-MSA-Information-Page
[6] National Institute on Aging. (2021). Pure Autonomic Failure (PAF). Retrieved from https://www.nia.nih.gov/health/pure-autonomic-failure-paf
[7] National Institute of Neurological Disorders and Stroke. (2021). Lewy Body Dementia. Retrieved from https://www.ninds.nih.gov/Disorders/All-Disorders/Lewy-Body-Dementia-Information-Page
[8] National Institute of Neurological Disorders and Stroke. (2021). Parkinson's Disease. Retrieved from https://www.ninds.nih.gov/Disorders/All-Disorders/Parkinsons-Disease-Information-Page
[9] Mayo Clinic. (2021). Neurocardiogenic syncope. Retrieved from https://www.mayoclinic.org/diseases-conditions/neurocardiogenic-syncope/symptoms-causes/syc-20374955
[10] Dysautonomia International. (n.d.). FD Facts. Retrieved from https://dysautonomiainternational.org/fd-facts/
- Science has shown an increasing interest in exploring the potential benefits of CBD for managing chronic medical conditions, including neurological disorders like dysautonomia and its associated symptoms.
- Aging and longevity research has long been focused on understanding the causes and effects of chronic diseases, such as neurodegenerative diseases like Parkinson's disease and Lewy body dementia, which often involve autonomic dysfunction and can reduce life expectancy.
- Health and wellness professionals have suggested integrating alternative therapies, such as chiropractic care, massage, and acupuncture, into the management of chronic medical conditions like dysautonomia, which can help improve quality of life and alleviate symptoms without relying solely on medical-conditions treatments like medications.
